> Merkliste Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp: E-Artikel Titel: Study of antirestenosis with the BiodivYsio dexamethasone‐eluting stent (STRIDE): A first‐in‐human multicenter pilot trial Beteiligte: Liu, Xiaoshun; Huang, Yanming; Hanet, Claude; Vandormael, Michel; Legrand, Victor; Dens, Joseph; Vandenbossche, Jean Luc; Missault, Luc; Vrints, Christiaan; De Scheerder, Ivan Erschienen: Wiley, 2003 Erschienen in: Catheterization and Cardiovascular Interventions Sprache: Englisch DOI: 10.1002/ccd.10636 ISSN: 1522-1946; 1522-726X Schlagwörter: Cardiology and Cardiovascular Medicine ; Radiology, Nuclear Medicine and imaging ; General Medicine Entstehung: Anmerkungen: Beschreibung: <jats:title>Abstract</jats:title><jats:p>The aim of this multicenter pilot study was to evaluate the acute safety and efficacy of the dexamethasone‐eluting stent (0.5 μg/mm<jats:sup>2</jats:sup> of stent) implanted in patients with de novo single‐vessel disease. This study included 71 patients, 42% of whom had unstable angina pectoris. An appropriately sized BiodivYsio Matrix Lo stent loaded with a total dexamethasone dose of 0.5 μg/mm<jats:sup>2</jats:sup> of stent was used. Technical device success rate was 95%. Six‐month MACE occurred in two patients (3.3%). Binary restenosis rate was 13.3%. Late loss was 0.45. Late loss and percent diameter stenosis were lower in the unstable angina pectoris patients compared to the stable patients (0.32 ± 0.39 vs. 0.60 ± 0.55 mm, <jats:italic>P</jats:italic> < 0.07, and 26.86 ± 14 vs. 38.40 ± 16%, <jats:italic>P</jats:italic> < 0.02). This study demonstrated the feasibility and safety of the implantation of a dexamethasone‐eluting stent and its effect on in‐stent neointimal hyperplasia. Catheter Cardiovasc Interv 2003;60:172–178. © 2003 Wiley‐Liss, Inc.</jats:p>